Biomimetic biodegradable artificial antigen presenting cells synergize with PD-1 blockade to treat melanoma.

ABSTRACT: Biomimetic materials that target the immune system and generate an anti-tumor responses hold promise in augmenting cancer immunotherapy. These synthetic materials can be engineered and optimized for their biodegradability, physical parameters such as shape and size, and controlled release of immune-modulators. As these new platforms enter the playing field, it is imperative to understand their interaction with existing immunotherapies since single-targeted approaches have limited efficacy. Here, we investigate the synergy between a PLGA-based artificial antigen presenting cell (aAPC) and a checkpoint blockade molecule, anti-PD1 monoclonal antibody (mAb). The combination of antigen-specific aAPC-based activation and anti-PD-1 mAb checkpoint blockade induced the greatest IFN-γ secretion by C

SUBMITTER: Kosmides AK 

PROVIDER: S-EPMC5207804 | biostudies-literature | 2017 Feb

REPOSITORIES: biostudies-literature